Consistent Use of Dapivirine Vaginal Ring Could Offer More Than 75% HIV Protection, New Data Suggests
Seventy-five percent: That's how much HIV protection women might be able to expect from a flexible silicone ring loaded with the antiretroviral medicine dapivirine when they put it in their vaginas and leave it there.
Rilpivirine (Edurant) remained detectable in plasma and female genital tract fluids for 18 months or more after a single injection of a long-acting non-nucleoside for HIV pre-exposure prophylaxis (PrEP).
Twice-daily oral maraviroc (Selzentry, Celsentri) failed to prevent SIV infection in infant macaques orally exposed to the virus, but the findings do not rule out potential use in human infants.
No woman taking daily maraviroc pre-exposure prophylaxis (PrEP) with or without tenofovir (TDF, Viread) or emtricitabine (FTC, Emtriva) became infected with HIV through 48 weeks in a randomized, double-blind, 188-woman U.S. study.
CATIE looks at some of the approaches in Canada and globally that help improve sex workers' access to HIV prevention and care services in a criminalized environment.
CHAMP: Mobilizing People Living With HIV and Allies to Champion HIV Prevention and Care in Ethno-Racial Communities
CHAMP (Community Champions HIV/AIDS Advocates Mobilization Project) evaluated two innovative and culturally relevant training programs to reduce HIV stigma and promote the championing of HIV-related issues amongst Asian, Black and Latino communities ...
On behalf of IFARA, Fred Schaich spoke with Zeda Rosenberg at this year's International AIDS Conference about final trial results showing the safety and efficacy -- when used -- of a vaginal ring in preventing HIV.
A new exploratory analysis of data from the ASPIRE study has found that using a drug-infused vaginal ring most or all of the time reduced the risk of HIV infection in women by at least 56 percent.
Three studies conducted by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in rural and urban sub-districts of the KwaZulu-Natal province provide new insights into the engine that drives HIV transmission in the country. They a...
Long-acting anti-HIV drugs have been in development longer than their oral, immediate-release counterparts. Some of the reasons for the longer development of these drugs arise because these formulations are new and have not been previously been teste...